SAN DIEGO, April 8, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.
"Initiation of QUANTUM-R is an important step in the development of quizartinib, and the trial will continue to be a central focus for our team going forward. We believe quizartinib has the potential to help patients with relapsed/refractory FLT3-ITD positive AML. Importantly, the trial design allows for patients in the quizartinib arm to continue to receive quizartinib as a continuous maintenance therapy following a transplant, which has the potential to increase duration of remission and overall survival," said Mike Martino, CEO of Ambit.
The trial will be conducted in FLT3-ITD positive AML patients over the age of 18 who have relapsed from, or are refractory to, frontline chemotherapy, including those patients relapsing following hematopoietic stem cell transplantation (HSCT). Patients will be dosed continually until disease progression or intolerable toxicity. Patients who proceed to HSCT after quizartinib treatment will be able to reinitiate treatment with quizartinib following the transplant.
The trial is expected to enroll approximately 326 patients in the United States, Western Europe, Canada and Australia. The primary endpoint for the Phase 3 clinical trial will be overall survival. An interim analysis will be conducted and will include an adaptive design component that will allow the Data Safety Monitoring Board (DSMB) to increase the number of patients, if warranted. Enrollment is expected to be completed in the second half of 2015, assuming there is no increase in the number of patients following the interim analysis.
"We are excited about starting the Phase 3 trial," said Athena Countouriotis, Chief Medical Officer at Ambit. "Based on the survival data with quizartinib in over 400 patients in two Phase 2 trials, as well as data collected from historical databases and recently published data from a similar Phase 3 study, we believe QUANTUM-R is designed to highlight the clinical benefits of quizartinib, and support its worldwide approval."
The Phase 3 trial follows completion of the Phase 2 and Phase 2b clinical trials, which demonstrated the key clinical benefits of quizartinib as a monotherapy, including a high response rate in relapsed/refractory FLT3-ITD positive patients; a substantial number of patients who were bridged to a potentially curative HSCT; and median overall survival in FLT3-ITD positive patients which compared favorably to historical survival data reported for FLT3-ITD positive and negative AML patients. Results from these studies were presented at medical conferences in 2012 and 2013.
Quizartinib is a once-daily, orally administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML. It is currently in development for the treatment of both newly diagnosed and relapsed FLT3-ITD positive and negative AML patients. Both the U.S. Food and Drug Administration (FDA) and European Commission have granted orphan drug designation to quizartinib for the treatment of AML.
About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FLT3 and is currently under clinical development in patients with relapsed/refractory AML and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following an HSCT. In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the future development and therapeutic potential of quizartinib. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Andrew McDonald, Ph.D.
Executive Director, Investor Relations & Corp Comm
LifeSci Advisors, LLC
Ambit Biosciences Corporation
SOURCE Ambit Biosciences